Research programme: infectious diseases therapeutics - Abivax

Drug Profile

Research programme: infectious diseases therapeutics - Abivax

Alternative Names: ABX 221; ABX 309; ABX 544

Latest Information Update: 09 Sep 2016

Price : $50

At a glance

  • Originator Abivax
  • Class Antivirals; Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chikungunya virus infections; Dengue; Ebola virus infections

Most Recent Events

  • 09 Sep 2016 Preclinical trials in Ebola virus infections, Chikungunya virus infections in France (Parenteral) (Abivax pipeline, September 2016)
  • 09 Sep 2016 Abivax plans phase I trials in Chikungunya virus infections, Dengue, and Ebola virus infections in the year 2017 (Abivax pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top